Kevin Coker
Co-Founder & CEO , Proxima Clinical Research
Kevin Coker is the Co-Founder and CEO of Proxima Clinical Research a partner for the emerging biotech and medical device industry. Over his career, Mr. Coker has served in a number of executive roles. Previously, he was CEO and Director of MolecularMatch, a software company dedicated to helping laboratories interpret next generation sequencing tests for clinical practice. He served as the Vice President and Oncology Franchise Lead for Worldwide Clinical Trials, a global CRO working in over 50 countries, and the Vice President of Research for McKesson/US Oncology. Mr. Coker is currently a Board Director for Volumetric, a 3D bioprinting company focused on making the world’s first 3D printed liver and is an advisor for Bioverge, an investment platform focused on life science companies.
Mr. Coker received a B.S. in Biology from the University of Central Arkansas, a M.S. in Pathology from the University of Arkansas for Medical Sciences, and J.D. and M.P.H. degrees from Case Western Reserve University. He is as a certified clinical molecular biologist CLSp(MB) and Regulatory Affairs certified RAC (US). He is the former Chair of the Ethics Committee for Regulatory Affairs Professional Society (RAPS) as well as past Board Member and served as an Assistant Attorney General for the State of Arkansas. He has been involved in over hundred clinical trials for pharmaceutical companies pursuing marketing indications and been involved in dozens of regulatory submissions for both biotech and medical device companies.
